{"nctId":"NCT01466192","briefTitle":"Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients","startDateStruct":{"date":"2012-05"},"conditions":["Chronic Hepatitis C"],"count":108,"armGroups":[{"label":"MP-424","type":"EXPERIMENTAL","interventionNames":["Drug: MP-424 (generic name:Telaprevir)","Drug: Ribavirin","Drug: Peginterferon alfa-2b"]}],"interventions":[{"name":"MP-424 (generic name:Telaprevir)","otherNames":[]},{"name":"Ribavirin","otherNames":[]},{"name":"Peginterferon alfa-2b","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Genotype 2, chronic hepatitis C\n* Relapsers (patient who relapsed after previous treatment)\n* Able and willing to follow contraception requirements\n\nExclusion Criteria:\n\n* Cirrhosis of the liver or hepatic failure\n* Hepatitis B surface antigen-positive or HIV antibodies-positive\n* History of, or concurrent hepatocellular carcinoma\n* History of, or concurrent depression, schizophrenia,; or suicide attempt in the past\n* Pregnant, lactating, or suspected pregnant patients, or male patients whose female partner is pregnant","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Undetectable HCV RNA at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":12,"n":108},"commonTop":["Anaemia","Pyrexia","Malaise","White blood cell count decreased","Platelet count decreased"]}}}